Roll-over Study to Allow Continued Access to Ribociclib

NCT05161195 · clinicaltrials.gov ↗

PHASE4

Phase

ACTIVE_NOT_RECRUITING

Status

134

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Ribociclib
DRUG: Letrozole
DRUG: Anastrozole
DRUG: Goserelin
DRUG: Tamoxifen
DRUG: Fulvestrant

Sponsor

Novartis Pharmaceuticals